Navigation Links
Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
Date:6/26/2012

SILVER SPRING, Md., June 26, 2012 /PRNewswire-USNewswire/ -- A new study on the effects of lorcaserin, a drug recently recommended for approval by an FDA advisory panel for the treatment of obesity, was just published in the scientific journal Obesity.  The journal is published by The Obesity Society (TOS), the leading scientific organization in North America dedicated to the study of obesity.  Authors include several TOS members including Patrick O'Neil, PhD, President, and Steven Smith, MD, Vice-President of TOS.

(Logo: http://photos.prnewswire.com/prnh/20120531/DC16753LOGO )

The study, titled BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus) evaluated 604 obese and overweight participants with type 2 diabetes in a double-blind placebo-controlled randomized trial over a one-year treatment period. Although all participants received systematic lifestyle change counseling, those on the medication lost 4.5 – 5.0% of their initial bodyweight compared to a loss of 1.5% by patients on the inactive placebo. According to lead author O'Neil, "That's a very meaningful difference in weight loss for this population. Importantly, the patients on active medication also showed much greater improvement on a key measure of blood glucose control."

Lorcaserin is a selective serotonin receptor agonist that works specifically on appetite signals in the brain. It has been developed by Arena Pharmaceuticals, which sponsored the trial. In previous clinical trials, lorcaserin decreased body weight in non-diabetic overweight and obese individuals. Although current American Diabetes Association treatment guidelines recommend that individuals with type 2 diabetes achieve modest weight loss (5–7%) to improve glycemic control, weight loss has historically been more difficult to achieve among patients with type 2
'/>"/>

SOURCE The Obesity Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MedVantx MedStart™ Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
2. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
3. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
4. NAMS Journal Menopause Reflects on the WHI 10 Years Later
5. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
6. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
7. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
8. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
9. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
10. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
11. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... , July 29, 2014 New technology ... which could allow physicians to see and assess brain ... promise, according to study authors who released their findings ... th Annual Meeting in Colorado Springs, ... advance the field of neurointervention, a specialty that facilitates ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... Fla., May 08, 2007 /PRNewswire-FirstCall/ --,Viragen, Inc. ... a sponsored in vitro study conducted at ... (multi-,subtype, human alpha interferon) suppressed development of,resistant ... degree than,recombinant alpha interferon. The study has ...
... New Economic Analyses of School and Daycare ... Cost Savings for,Community at Large, TORONTO, May ... research results showing that use of FluMist(R),(Influenza ... school,settings may help reduce the burden of ...
Cached Medicine Technology:Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 2Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 3Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8
(Date:7/29/2014)... a well-known online supplier, now allows worldwide clients to ... by providing graceful and sexy lingerie collection for August. ... sexy dresses , designed and developed by top ... price into consideration. Worry no more, because VogueQueen.com launches ... for all clients. , VogueQueen.com’s top designers sincerely ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that the program ... Alison Freeman wanted to show her patients some alternative ways ... finding out more about this method can easily access it ... currently available in online format. , In the eBook, sufferers ... tips that can help them achieve a cure for herpes. ...
(Date:7/29/2014)... 29, 2014 The Natural Multiple Sclerosis ... inside story to Gary M. Levin’s cure program. ... method for this serious disorder. Levin says that multiple ... that can be found in patients. , Dr. ... For many years, Levin has worked with patients suffering ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica in ... method of naturally overcoming sciatica, in less than 7 ... ensure sufferers that the cure is simple to achieve, ... new method is described as very fast, as it ... 8 minutes per day treatment plan. , Read ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... Highlights: ... - 100% contract renewal for 11 consecutive annual cycles ... initiative acquisition - Diluted earnings per share of ... Service,Corporation (Nasdaq: PRSC ) today announced financial results for the third,quarter ended ...
... cholesterol-busting drugs could be lifesavers, study suggsts , TUESDAY, ... drugs after coronary artery bypass graft (CABG) surgery reduces ... The study, from the Cleveland Clinic, included more than ... late 2005. The overall incidence of post-operative stroke one ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today announced ... investment activity. "The third quarter was a good ... per share up 8%," commented Douglas M. Pasquale, NHP,s,President ... $150,million of accretive investments, bringing our total for 2007 ...
... Nov. 6 The first annual HealthSaver,Caffeinated ... emerging,health care discount service, found that the ... followed by Tampa, Miami, Phoenix and Atlanta. ... The least caffeinated cities are San Francisco/Oakland, ...
... underperformance and ... deterioration of shareholder value., ANAHEIM, Calif., Nov. ... benefit and pension fund trustees and,administrators are in Anaheim, ... conference. The conference is,considered a premier marketing opportunity for ...
... Research has shown convincing evidence that dietary patterns ... decline and dementia risk. An article published in Annals ... on the benefits of diets high in fruit, vegetables, ... reducing dementia risk. , Adults with diabetes are ...
Cached Medicine News:Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 2Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 3Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 4Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 5Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 6Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 7Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 8Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 9Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 2Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 3Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 4Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 5Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 6Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 7Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 8Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 9Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 11Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 12Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 2Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 3Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 4Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 5Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 6Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 7Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: